… CNS applications via new research partnership with Rett Syndrome Research Trust Completed divestment of sepofarsen … development of these programs for patients with LCA10 and Ushersyndrome. The transaction agreement provided ProQR with …
Reported rapid, significant and durable improvements in vision at twelve months
Concordant improvement in key secondary outcome measures
The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile
Strengthens confidence